Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1744 CL crossover exercise endurance study in COPD
2009-014416-35Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Endurance time during constant work rate cycle ergometry. Started Nov 2009; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-014416-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014416-35.